Lilly Phase 1 Study Starts for Potential Covid-19 Antibody Treatment

Eli Lilly and Co. said its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralizing antibody treatment designed to fight Covid-19.
Junshi Biosciences and Lilly are co-developing the investigational medicine, referred to as JS016, with Junshi leading development in Greater China, Lilly said. Lilly said it has exclusive rights in the rest of the world and will begin dosing patients in a complementary Phase 1 study in the U.S. in the coming days.
Both Phase 1 studies aim to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who haven’t been diagnosed with Covid-19.
Lilly shares rose 1.2% to $150.99 premarket.
This is Lilly’s second neutralizing antibody to start clinical trials, following LY-CoV555, which recently entered Phase 1 and is currently being tested in hospitalized Covid-19 patients.

https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Lilly-Phase-1-Study-Starts-for-Potential-Covid-19-Antibody-Treatment-30739212/